Vaccines found Vaccines on trial Adults on trials Confirmed cases People vaccinated

0

141↑

2,3706↑

9,561,229↑

0

Last updated:

All Covid-19 vaccine candidates


University of Oxford

Pre-clinical
Phase One
Phase Two
Phase Three
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: Up to 10,260 adults and children across the UK are enrolled
  • Country: England
  • Pharmaceutical form: Solution for injection
  • Product name: ChAdOx1 nCoV-19
  • ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus)
  • Ethics Committee Opinion of the trial application: Favorable
  • Source link 1
    Source link 2

CanSino Biological Inc./Beijing Institute of Biotechnology

Pre-clinical
Phase One
Phase Two
more info
  • Platform: Non-Replicating Viral Vector
  • Group Size: 500 adults over 18 in Wuhan are enrolled
  • Country: China
  • Pharmaceutical form: Solution for injection
  • Outcome: Anti-S antibody IgG titer on day 28 post vaccination
  • Ethics Committee Opinion of the trial application: N/A
  • Source link

Moderna/NIAID

Pre-clinical
Phase One
Phase Two
more info
  • Platform: RNA
  • Group Size: 155 adults
  • Country: Massachusetts, United States
  • Pharmaceutical form: Solution for injection
  • Requires multiple injections
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:mRNA-1273
  • Source link

Wuhan Institute of Biological Products/Sinopharm

Pre-clinical
Phase One
Phase Two
more info
  • Platform: Inactivated vaccine
  • Group Size: 1,456 healthy subjects aged 6 years and above
  • Country: China
  • Pharmaceutical form: Solution for injection
  • Outcome:1)Incidence of Serious Adverse Events, 2) Four-fold growth rate and antibody level (GMT, GMI) of serum antibody against COVID-19
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A
Source link

Wuhan Institute of Biological Products/Sinopharm

Pre-clinical
Phase One
Phase Two
more info
  • Platform: inactivated vaccine
  • Group Size: 2,004 healthy subjects aged 3 years and above
  • Country: China
  • Pharmaceutical form: Solution for injection
  • Outcome:1)Incidence of Serious Adverse Events, 2) Four-fold growth rate and antibody level (GMT, GMI) of serum antibody against COVID-19
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A
  • Source link

Sinovac

Pre-clinical
Phase One
Phase Two
more info
  • Platform: inactivated vaccine
  • Group Size: 422 healthy adults aged 60 Years and older
  • Country: China
  • Pharmaceutical form: Solution for injection, two doses
  • Outcome:Neutralizing antibody assay will be performed using the micro-neutralization method.
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A
  • Source link

Novavax

Pre-clinical
Phase One
Phase Two
more info
  • Platform: Protein Subunit
  • Group Size: 131 healthy adults
  • Country: Maryland, United States
  • Pharmaceutical form: Solution for injection, two doses
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A
  • Source link

BioNTech/Fosun Pharma/Pfizer

Pre-clinical
Phase One
Phase Two
more info
  • Platform: 3 LNP-mRNAs
  • Group Size: 196 healthy adults (18-64 years)
  • Country: Germany, China, New York-United States
  • Pharmaceutical form: Solution for injection
  • Outcome:Functional antibody responses after the primary immunization.
  • Ethics Committee Opinion of the trial application: Favorable
  • Product name:N/A
  • Source link

Institute of Medical Biology , Chinese Academy of Medical Sciences

Pre-clinical
Phase One
more info
  • Platform: Inactivated vaccine
  • Country: China
  • Group Size: N/A
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A

Inovio Pharmaceuticals

Pre-clinical
Phase One
more info
  • Platform: DNA plasmid vaccine with electroporation
  • Group Size: 40 healthy adults (18-50 years)
  • Country: Pennsylvania, United States
  • Pharmaceutical form: Solution for injection
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A
  • Source link

Imperial College London

Pre-clinical
Phase One
more info
  • Platform: RNA
  • Group Size: N/A
  • Country: UK
  • Pharmaceutical form: N/A
  • Outcome:N/A
  • Ethics Committee Opinion of the trial application: N/A
  • Product name:N/A
  • Source link

Genexine Consortium

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA Vaccine (GX-19)

Karolinska Institute / Cobra Biologics (OPENCORONA Project)

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA with electroporation

Osaka University/ AnGes/ Takara Bio

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA plasmid vaccine

Takis/Applied DNA Sciences/Evvivax

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA

Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: Plasmid DNA, Needle-Free Delivery

Zydus Cadila

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA plasmid vaccine

Zydus Cadila

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA plasmid vaccine

BioNet Asia

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA vaccine

University of Waterloo

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA vaccine

Entos Pharmaceuticals

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA vaccine

Symvivo

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: bacTRL-Spike

Beijing Minhai Biotechnology Co., Ltd.

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: Inactivated

Osaka University/ BIKEN/ NIBIOHN

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: TBD

Sinovac/Dynavax

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: Inactivated + CpG 1018

Valneva/Dynavax

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: Inactivated + CpG 1018

Research Institute for Biological Safety Problems, Rep of Kazakhstan

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: Inactivated

Codagenix/Serum Institute of India

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: Codon deoptimized live attenuated vaccines

Indian Immunologicals Ltd/Griffith University

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: Codon deoptimized live attenuated vaccines

GeoVax/BravoVax

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: MVA encoded VLP

See all 136 Vaccines

Janssen Pharmaceutical Companies

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Ad26

ReiThera/LEUKOCARE/Univercells

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Replication defective Simian Adenovirus (GRAd) encoding SARS-CoV-2 S

DZIF – German Center for Infection Research

Pre-clinical
more info
  • Platform: Non-replicating viral vector
  • Group size: 0
  • Type of candidate vaccine: MVA-S encoded

IDIBAPS-Hospital Clinic, Spain

Pre-clinical
more info
  • Platform: Non-replicating viral vector
  • Group size: 0
  • Type of candidate vaccine: MVA-S

Altimmune

Pre-clinical
more info
  • Platform: Non-replicating viral vector
  • Group size: 0
  • Type of candidate vaccine: adenovirus-based NasoVAX expressing SARS2-CoV spike protein

ImmunityBio, Inc.

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid

Greffex

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Ad5 S (GREVAX™ platform)

Stabilitech Biopharma Ltd

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Oral Ad5 S

Valo Therapeutics Ltd

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: adenovirus-based + HLA-matched peptides

Vaxart

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Oral Vaccine platform

Centro Nacional Biotecnología (CNB-CSIC), Spain

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: MVA expressing structural proteins

University of Manitoba

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Dendritic cell-based vaccine

University of Georgia/University of Iowa

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein

Bharat Biotech/Thomas Jefferson University

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA

National Center for Genetic Engineering and Biotechnology (BIOTEC) /GPO, Thailand

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant

Chulalongkorn University/GPO, Thailand

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: RBD protein fused with Fc of IgG + Adj.

AdaptVac (PREVENT-nCoV consortium)

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Capsid-like Particle

ExpreS2ion

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Drosophila S2 insect cell expression system VLPs

IMV Inc

Pre-clinical
more info
  • Platform: Peptide antigens formulated in LNP
  • Group size: 0
  • Type of candidate vaccine: Peptide antigens formulated in LNP

WRAIR/USAMRIID

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: S protein

National Institute of Infectious Disease, Japan

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: S protein +Adjuvant

Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: VLP-recombinant protein + Adjuvant

Clover Biopharmaceuticals Inc./GSK/Dynavax

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Native like Trimeric subunit Spike Protein vaccine

Univ. of Pittsburgh

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: microneedle arrays S1 subunit

Vaxil Bio

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Peptide

Biological E Ltd

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Adjuvanted protein subunit (RBD)

Flow Pharma Inc

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Peptide

AJ Vaccines

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: S protein

Generex/EpiVax

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Ii-Key peptide

EpiVax/Univ. of Georgia

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: S protein

EpiVax

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Protein Subunit EPV-CoV-19

Sanofi Pasteur/GSK

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: S protein (baculovirus production)

Heat Biologics/Univ. Of Miami

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: gp-96 backbone

University of Queensland/GSK/Dynavax

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Molecular clamp stabilized Spike protein

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Peptide vaccine

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Subunit vaccine

Baylor College of Medicine

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: S1 or RBD protein

iBio/CC-Pharming

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Subunit protein, plant produced

Saint-Petersburg scientific research institute of vaccines and serums

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Recombinant protein, nanoparticles (based on S-protein and other epitopes)

Innovax/Xiamen Univ./GSK

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: COVID-19 XWG-03 truncated S (spike) proteins

VIDO-InterVac, University of Saskatchewan

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Adjuvanted microsphere peptide

OncoGen

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Synthetic Long Peptide Vaccine candidate for S and M proteins

MIGAL Galilee Research Institute

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Oral E. coli-based protein expression system of S and N proteins

LakePharma, Inc.

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Nanoparticle vaccine

Vaxine Pty Ltd/Medytox

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Recombinant spike protein with Advax™ adjuvant

Quadram Institute Biosciences

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: OMV-based vaccine

BiOMViS Srl/Univ. of Trento

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: OMV-based vaccine

Lomonosov Moscow State University

Pre-clinical
more info
  • Platform: Protein subunit
  • Group size: 0
  • Type of candidate vaccine: structurally modified spherical particles of the tobacco mosaic virus (TMV)

University of Alberta

Pre-clinical
more info
  • Platform: Protein subunit
  • Group size: 0
  • Type of candidate vaccine: Spike-based

AnyGo Technology

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Recombinant S1-Fc fusion protein

Yisheng Biopharma

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Recombinant protein

Vabiotech

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Recombinant S protein in IC-BEVS

Applied Biotechnology Institute, Inc.

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Orally delivered, heat stable subunit

Medigen Vaccine Biologics Corporation/NIAID/Dynavax

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: S-2P protein + CpG 1018

Axon Neuroscience SE

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Peptides derived from Spike protein

MOGAM Institute for Biomedical Research, GC Pharma

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Protein Subunit

Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Adjuvanted recombinant protein (RBD-Dimer)

Neovii/Tel Aviv University

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: RBD-based

Kentucky Bioprocessing, Inc

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: RBD-based

Intravacc/Epivax

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Outer Membrane Vesicle (OMV)-peptide

KU Leuven

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: YF17D Vector

Zydus Cadila

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Measles Vector

Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research/Merck

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Measles Vector

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Measles Vector

DZIF – German Center for Infection Research

Pre-clinical
more info
  • Platform: Live attenuated virus
  • Group size: 0
  • Type of candidate vaccine: Measles Virus (S, N targets)

Tonix Pharma/Southern Research

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Horsepox vector expressing S protein

BiOCAD and IEM

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)

Fundação Oswaldo Cruz and Instituto Buntantan

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Attenuated Influenza expressing an antigenic portion of the Spike protein

University of Hong Kong

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Attenuated Influenza expressing an antigenic portion of the Spike protein

IAVI/Merck

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein.

University of Western Ontario

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: VSV-S

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: VSV vector

UW–Madison/FluGen/Bharat Biotech

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: M2-deficient single replication (M2SR) influenza vector

Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)

The Lancaster University, UK

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Avian paramyxovirus vector (APMV)

Translate Bio/Sanofi Pasteur

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: LNP-mRNA

CanSino Biologics/Precision NanoSystems

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: LNP-mRNA

Fudan University/ Shanghai JiaoTong University/RNACure Biopharma

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: LNP-encapsulated mRNA cocktail encoding VLP

Centro Nacional Biotecnología (CNB-CSIC), Spain

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: Replicating Defective SARS-CoV-2 derived RNAs

University of Tokyo/ Daiichi-Sankyo

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: LNP-encapsulated mRNA

BIOCAD

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: Liposome-encapsulated mRNA

RNAimmune, Inc.

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: Several mRNA candidates

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: mRNA

China CDC/Tongji University/Stermina

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: mRNA

Arcturus/Duke-NUS

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: mRNA

Curevac

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: mRNA

eTheRNA

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: mRNA in an intranasal delivery system

Greenlight Biosciences

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: mRNA

IDIBAPS-Hospital Clinic, Spain

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: mRNA

Mahidol University/ The Government Pharmaceutical Organization (GPO)

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: VLP + Adjuvant

Navarrabiomed, Oncoimmunology group

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: Virus-like particles, lentivirus and baculovirus vehicles

Saiba GmbH

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: Virus-like particle, based on RBD displayed on virus-like particles

Medicago Inc.

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: Plant-derived VLP

Imophoron Ltd and Bristol University’s Max Planck Centre

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: ADDomerTM multiepitope display

Doherty Institute

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: Unknown

OSIVAX

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: VLP

ARTES Biotechnology

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: eVLP

Univ. of Sao Paulo

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: VLPs peptides/whole virus

ImmunoPrecise

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Spike-based (epitope screening)

Tulane University

Pre-clinical
more info
  • Platform: Unknown
  • Group size: 0
  • Type of candidate vaccine: Unknown

Université Laval

Pre-clinical
more info
  • Platform: Unknown
  • Group size: 0
  • Type of candidate vaccine: Unknown

Massachusetts Eye and Ear/ Massachusetts General Hospital/ AveXis

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: Adeno-associated virus vector (AAVCOVID)

ImmunityBio, Inc. & NantKwest, Inc.

Pre-clinical
more info
  • Platform: Non-Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid

MOGAM Institute for Biomedical Research, GC Pharma

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Protein Subunit

Intravacc/Epivax

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Outer Membrane Vesicle (OMV)-subunit

Chula Vaccine Research Center

Pre-clinical
more info
  • Platform: DNA
  • Group size: 0
  • Type of candidate vaccine: DNA with electroporation

Baiya Phytopharm/ Chula Vaccine Research Center

Pre-clinical
more info
  • Platform: Protein Subunit
  • Group size: 0
  • Type of candidate vaccine: Plant-based subunit(RBD-Fc + Adjuvant)

Chula Vaccine Research Center/ University of Pennsylvania

Pre-clinical
more info
  • Platform: RNA
  • Group size: 0
  • Type of candidate vaccine: LNP-mRNA

(new) Israel Institute for Biological Research/Weizmann Institute of Science

Pre-clinical
more info
  • Platform: Replicating Viral Vector
  • Group size: 0
  • Type of candidate vaccine: VSV-S

(new) IrsiCaixa AIDS Research/ IRTACReSA/ Barcelona Supercomputing Centre/ Grifols

Pre-clinical
more info
  • Platform: VLP
  • Group size: 0
  • Type of candidate vaccine: S protein integrated in HIV VLPs
DISCLAIMER:

These information are acquired from the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global pandemic of the novel coronavirus (SARS-CoV-2).

Home All candidates Sources About Vacine types

Contact:

E-mail: [email protected]